Advertisement
FATE vs PTN
Which Stock Would AI Choose? Fate Therapeutics (FATE) vs. Palatin Technologies (PTN) Stock Comparison
Key Takeaways
- Both FATE and PTN are clinical-stage biotechnology companies, but they pursue different science: Fate Therapeutics develops off-the-shelf cell therapies, while Palatin Technologies targets the melanocortin receptor (MCR) system for obesity and related conditions.
- FATE has shown stronger recent momentum, rising more than 100% year-to-date, while PTN has been comparatively more volatile following a reverse stock split and a listing transfer to Nasdaq.
- FATE holds a longer cash runway (guided into 2028) versus PTN, whose cash and expected receivables are projected to fund operations only into mid-2027.
- Tickeron AI Verdict: FATE — the AI currently favors Fate Therapeutics based on trend consistency, relative price stability, a longer funding runway, and a broader clinical pipeline.
- For more detail on each name, explore FATE Major News and FATE Today's Price Move, as well as PTN Major News and PTN Today's Price Move.
- To see which automated strategies are currently favored by the market, explore Trending AI Robots.
Introduction
Investors screening small-cap and clinical-stage biotechnology often weigh two very different risk-reward profiles. FATE (Fate Therapeutics) is advancing off-the-shelf, stem-cell-derived cell therapies for cancer and autoimmune disease, while PTN (Palatin Technologies) is developing melanocortin receptor agonists aimed at rare obesity and metabolic disorders. Both companies are pre-revenue or near-pre-revenue, making cash runway, clinical catalysts, and market positioning central to any comparison. This stock comparison is most relevant to growth-oriented traders and investors who understand that binary clinical outcomes can drive sharp, sentiment-led price swings.
FATE Overview and Recent Performance
Fate Therapeutics is a clinical-stage biopharmaceutical company building off-the-shelf, induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) T-cell and natural killer (NK) cell immunotherapies. Its pipeline, including FT819 and FT839, targets both hematologic cancers and autoimmune conditions such as systemic lupus erythematosus (SLE). In recent weeks, the company showcased data at the European Congress of Rheumatology (EULAR), reporting continued clinical improvement and a favorable tolerability profile for FT819 in SLE patients.
Financially, FATE remains in investment mode, with quarterly revenue in the low single-digit millions and recurring net losses, though losses have narrowed year over year. The company guided to an operating runway into 2028, supported by roughly $175 million in cash and investments, which has helped temper near-term dilution concerns. The stock has rallied strongly over the past year, and while recent weeks have brought some profit-taking and elevated volatility, broader market positioning remains notably improved.
PTN Overview and Recent Performance
Palatin Technologies is a biopharmaceutical company focused on medicines that modulate the melanocortin receptor (MCR) system. Its lead programs are selective MC4R (melanocortin-4 receptor) agonists intended for syndromic and rare obesity disorders, including hypothalamic obesity and Prader-Willi syndrome. The company is also advancing oral and once-weekly peptide candidates designed to reduce side effects such as hyperpigmentation.
Recent market activity for PTN has been shaped by a 1-for-50 reverse stock split, a transfer of its listing to Nasdaq, and a meaningful but narrowing loss profile. Collaboration and license revenue grew sharply in fiscal 2026, driven by a Boehringer Ingelheim partnership for retinal diseases and a sublicense of its PL-9643 dry-eye program. Cash and expected receivables are projected to fund operations into mid-2027, a tighter runway than peers. The stock has experienced substantial volatility in recent weeks, reflecting both speculative enthusiasm around obesity assets and ongoing funding risk.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own strategy, timeframe, risk profile, and performance history. Because market conditions change continuously, not every bot is equally well-suited to the current environment. Tickeron curates a shortlist of the most relevant and effective strategies in its Trending AI Robots section, highlighting the bots whose recent signals and statistics stand out. These automated strategies vary widely — from short-term momentum to longer-horizon swing approaches — giving traders a way to compare quantitative performance across styles. Exploring the Trending AI Robots page can help investors identify which algorithms are currently positioned for prevailing market dynamics.
Head-to-Head Comparison
The two companies diverge sharply on business model and therapeutic focus. FATE operates a broad, platform-based cell therapy approach with multiple clinical candidates and a runway into 2028, while PTN is more narrowly concentrated on obesity-related melanocortin assets with a shorter, mid-2027 runway.
On momentum, FATE has delivered a steadier upward trend and broader sell-side coverage, whereas PTN has shown higher price swings and thinner analyst coverage, albeit with notably high average price targets. Risk profiles also differ: FATE carries clinical and cash-burn risk common to cell therapy, while PTN faces competitive pressure in a crowded obesity field and more immediate funding constraints. Sector exposure is a final contrast — immuno-oncology and autoimmune therapy versus metabolic and endocrine disease.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would currently lean toward FATE. Fate Therapeutics displays more consistent trend structure, relatively greater price stability, a longer cash runway into 2028, and a diversified pipeline that provides multiple potential catalysts. Palatin Technologies carries genuine upside potential given its differentiated obesity programs and strong analyst price targets, but its shorter runway and higher recent volatility introduce greater uncertainty. The AI's preference for FATE reflects a probabilistic weighting toward trend consistency and relative positioning rather than a definitive prediction of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a StrongBuy and PTN is a Hold.
FATE in +3.98% Uptrend, growing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where FATE advanced for three days, in 214 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for FATE's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FATE as a result. In 85 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for FATE turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 49 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for FATE entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.433) is normal, around the industry mean (3.498). P/E Ratio (-1.748) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (45.045) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. FATE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for PTN turns positive, indicating new upward trend
PTN saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In 72 of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PTN's RSI Indicator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for PTN just turned positive on November 03, 2026. Looking at past instances where PTN's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +26.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTN advanced for three days, in 182 of 218 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PTN broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PTN entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.668) is normal, around the industry mean (3.498). P/E Ratio (-2.118) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.507) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. PTN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FATE | PTN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 62 | 81 | |
P/E GROWTH RATING 1..100 | 13 | 98 | |
SEASONALITY SCORE 1..100 | 50 | 38 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PTN's Valuation (41) in the Biotechnology industry is in the same range as FATE (50). This means that PTN’s stock grew similarly to FATE’s over the last 12 months.
PTN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as FATE (100). This means that PTN’s stock grew similarly to FATE’s over the last 12 months.
FATE's SMR Rating (98) in the Biotechnology industry is in the same range as PTN (100). This means that FATE’s stock grew similarly to PTN’s over the last 12 months.
FATE's Price Growth Rating (62) in the Biotechnology industry is in the same range as PTN (81). This means that FATE’s stock grew similarly to PTN’s over the last 12 months.
FATE's P/E Growth Rating (13) in the Biotechnology industry is significantly better than the same rating for PTN (98). This means that FATE’s stock grew significantly faster than PTN’s over the last 12 months.
| FATE | PTN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | 1 day ago 79% |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 88% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 78% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Advances ODDS (%) | 8 days ago 87% | 3 days ago 83% |
| Declines ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FATE’s FA Score shows that 1 FA rating(s) are green while PTN’s FA Score has 0 green FA rating(s).
- FATE’s FA Score: 1 green, 4 red.
- PTN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FATE’s TA Score shows that 4 TA indicator(s) are bullish while PTN’s TA Score has 4 bullish TA indicator(s).
- FATE’s TA Score: 4 bullish, 4 bearish.
- PTN’s TA Score: 4 bullish, 4 bearish.
Price Growth
FATE (@Biotechnology) experienced а -23.21% price change this week, while PTN (@Biotechnology) price change was +13.95% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
FATE is expected to report earnings on Mar 01, 2027.
PTN is expected to report earnings on Nov 13, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
FATE and
Correlation & Price change
A.I.dvisor indicates that over the last year, FATE has been loosely correlated with NKTX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then NKTX could also see price increases.
| Ticker / NAME | Correlation To FATE | 1D Price Change % | ||
|---|---|---|---|---|
| FATE | 100% | -9.32% | ||
| NKTX - FATE | 45% Loosely correlated | +9.63% | ||
| VCYT - FATE | 44% Loosely correlated | +4.36% | ||
| SANA - FATE | 43% Loosely correlated | -5.76% | ||
| CABA - FATE | 43% Loosely correlated | N/A | ||
| PTN - FATE | 41% Loosely correlated | -0.44% | ||
More | ||||
PTN and
Correlation & Price change
A.I.dvisor indicates that over the last year, PTN has been loosely correlated with FATE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if PTN jumps, then FATE could also see price increases.
| Ticker / NAME | Correlation To PTN | 1D Price Change % | ||
|---|---|---|---|---|
| PTN | 100% | -0.44% | ||
| FATE - PTN | 41% Loosely correlated | -9.32% | ||
| MLTX - PTN | 35% Loosely correlated | +7.56% | ||
| VTGN - PTN | 35% Loosely correlated | +2.57% | ||
| MDGL - PTN | 32% Poorly correlated | +0.10% | ||
| RYTM - PTN | 30% Poorly correlated | -1.57% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AIYY | 7.29 | 0.14 | +1.96% |
| YieldMax AI Option Income Strategy ETF (AIYY) | |||
| SCHK | 36.54 | 0.47 | +1.30% |
| Schwab 1000 Index ETF (SCHK) | |||
| ESMV | 32.56 | 0.33 | +1.02% |
| iShares ESG Optimized MSCI USA Min Vol Factor ETF (ESMV) | |||
| UFEB | 39.75 | 0.26 | +0.66% |
| Innovator U.S. Equity Ultra Buffer ETF - February (UFEB) | |||
| WWJD | 39.84 | 0.07 | +0.18% |
| Inspire International ETF (WWJD) | |||